

CSD/BSE&NSE/2025-26  
July 28, 2025

To  
The Manager  
Department of Corporate Services  
BSE Limited  
25th Floor, P. J. Towers,  
Dalal Street, Mumbai - 400 001  
**Scrip Code: 543064**

To  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051  
**Scrip Symbol: COHANCE**

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform that the Board of Directors of the Company, by way of Circular Resolution passed today, i.e. July 28, 2025, has:

- a) noted the resignation of Dr. Sudhir Kumar Singh, who looks after the CDMO business, as Chief Executive Officer of the Company. In view of his resignation, he will cease to be a Key Managerial Personnel and Senior Management Personnel of the Company, effective from the close of working hours on July 31, 2025. However, he will continue to be available with the Company in terms of his contractual terms with the Company and to facilitate seamless transition of his duties and responsibilities. The resignation email dated June 18, 2025 along with reasons for the resignation, as received from Dr. Sudhir Kumar Singh is annexed herewith.
- b) based on the recommendations of the Nomination and Remuneration Committee, approved the appointment of Mr. Yann D'Herve as Chief Executive Officer – CDMO Business, and Senior Management Personnel of the Company, with effect from August 1, 2025. Mr. Yann will be based out of New Jersey, United States of America. The brief profile of Mr. Yann is annexed with this disclosure.

The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 on the captioned subject is annexed herewith.

This is for your information and record.

Thanking you.

Yours faithfully,  
For **Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

**Kundan Kumar Jha**  
*Company Secretary, Compliance Officer and Head-Legal*

Encl: as above

---

**Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad  
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.  
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,  
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.  
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | Company Email: [info@suvenpharm.com](mailto:info@suvenpharm.com)



**Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

1	<b>Name of the person</b>	<b>Dr. Sudhir Kumar Singh</b>	<b>Mr. Yann D'Herve</b>
2	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Resignation of Dr. Sudhir Kumar Singh, who looks after the CDMO business, as Chief Executive Officer of the Company. He will cease to be a Key Managerial Personnel and Senior Management Personnel of the Company, effective from the close of working hours on July 31, 2025. The resignation email dated June 18, 2025 received from Dr. Sudhir Kumar Singh is annexed herewith.	Appointment of Mr. Yann D'Herve as Chief Executive Officer – CDMO Business, and Senior Management Personnel of the Company, with effect from August 1, 2025. The brief profile of Mr. Yann is annexed with this disclosure.
3	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	Dr. Sudhir Kumar Singh will cease to be Key Managerial Personnel and Senior Management Personnel of the Company, effective from the close of working hours on July 31, 2025.	Mr. Yann D'Herve appointed as the Chief Executive Officer - CDMO Business, and Senior Management Personnel of the Company, with effect from August 1, 2025.
4	Brief Profile (in case of appointment)	Not applicable	Brief profile is annexed
5	Disclosure of relationship between directors (in case of appointment)	Not applicable	Not applicable

**Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.  
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.  
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | Company Email: [info@suvenpharm.com](mailto:info@suvenpharm.com)



## Profile of Mr. Yann D'Herve



Yann brings strong leadership capabilities, backed by a rich and diverse background across multiple businesses and roles. His experience spans manufacturing, strategic management, and commercial operations. With a career across multiple industries, including pharmaceuticals, healthcare, and chemicals. He has significant experience working with global markets, including India. Yann began his career in manufacturing, gaining hands-on experience in production and operations. He later moved to the commercial roles with increasing responsibilities handling drug substance, drug products and excipients.

Yann joins us from Evonik, where he held a variety of leadership roles over the years. Most recently, he served as Senior Vice President and General Manager of the Healthcare division, overseeing 2,600 employees across 9 manufacturing sites. In this role, he had full P&L responsibility, including for the CDMO business, with all teams and functions reporting directly to him. Yann holds a degree in Chemistry and an MBA.



---

**From:** Sudhirk singh [REDACTED]  
**Sent:** Wednesday, June 18, 2025 5:32:21 PM  
**To:** Gaurav Bahadur [REDACTED]  
**Subject:** FW: Stepping down as CEO

---

**From:** Sudhirk singh  
**Sent:** 18 June 2025 17:32  
**To:** Vivek Sharma [REDACTED] Arjun [REDACTED]  
**Subject:** Stepping down as CEO

Dear Vivek and Arjun

As discussed with you yesterday, I am going through some health issues and would like to slow down in current role and would not be able to spend full time as CEO, hence request you to look for the transition of my role and find a suitable candidate. However I will continue as per the contractual terms till the end of this yr. and will help you in On Boarding and hand over to new person. Let us start the planning of transition.

I thank you for giving me the opportunity to contribute to the Organization.

Thanks and regards

Sudhir